GlaxoSmithKline plc (NYSE:GSK) Given Average Rating of “Hold” by Brokerages

Shares of GlaxoSmithKline plc (NYSE:GSKGet Rating) have received an average rating of “Hold” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $1,248.67.

A number of brokerages have recently commented on GSK. Stifel Nicolaus began coverage on GlaxoSmithKline in a report on Monday, February 28th. They set a “hold” rating on the stock. JPMorgan Chase & Co. raised their price target on GlaxoSmithKline from GBX 1,740 ($21.90) to GBX 1,900 ($23.91) in a report on Thursday, April 28th. StockNews.com raised GlaxoSmithKline from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 11th. DZ Bank cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 11th. Finally, Barclays increased their price target on GlaxoSmithKline from GBX 1,775 ($22.34) to GBX 1,800 ($22.65) in a research report on Friday, April 29th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dodge & Cox boosted its position in GlaxoSmithKline by 0.6% during the 4th quarter. Dodge & Cox now owns 88,519,444 shares of the pharmaceutical company’s stock worth $3,903,707,000 after acquiring an additional 501,530 shares during the period. Fisher Asset Management LLC boosted its position in GlaxoSmithKline by 4.1% during the 1st quarter. Fisher Asset Management LLC now owns 18,967,209 shares of the pharmaceutical company’s stock worth $826,212,000 after acquiring an additional 750,042 shares during the period. Black Creek Investment Management Inc. boosted its position in GlaxoSmithKline by 0.4% during the 4th quarter. Black Creek Investment Management Inc. now owns 10,373,943 shares of the pharmaceutical company’s stock worth $457,491,000 after acquiring an additional 44,594 shares during the period. Renaissance Technologies LLC boosted its position in GlaxoSmithKline by 8.6% during the 4th quarter. Renaissance Technologies LLC now owns 10,225,421 shares of the pharmaceutical company’s stock worth $450,941,000 after acquiring an additional 811,000 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of GlaxoSmithKline by 32.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock worth $419,107,000 after purchasing an additional 2,362,274 shares in the last quarter. Hedge funds and other institutional investors own 32.76% of the company’s stock.

Shares of GSK opened at $44.75 on Tuesday. GlaxoSmithKline has a 12-month low of $37.80 and a 12-month high of $46.97. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.19 and a quick ratio of 0.95. The business’s fifty day moving average price is $44.45 and its 200 day moving average price is $43.63. The stock has a market capitalization of $113.75 billion, a PE ratio of 16.16, a price-to-earnings-growth ratio of 1.93 and a beta of 0.64.

GlaxoSmithKline (NYSE:GSKGet Rating) last issued its quarterly earnings results on Wednesday, April 27th. The pharmaceutical company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. The company had revenue of $13.12 billion for the quarter, compared to analyst estimates of $11.97 billion. GlaxoSmithKline had a return on equity of 28.13% and a net margin of 14.03%. As a group, research analysts anticipate that GlaxoSmithKline will post 3.18 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 1st. Shareholders of record on Friday, May 20th will be given a dividend of $0.3496 per share. The ex-dividend date of this dividend is Thursday, May 19th. This represents a $1.40 dividend on an annualized basis and a yield of 3.13%. GlaxoSmithKline’s payout ratio is presently 49.46%.

About GlaxoSmithKline (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.